RCT: Event-free survival with pembrolizumab in early triple-negative breast cancer.
11 Feb, 2022 | 08:35h | UTCEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (before publication): KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer – The ASCO Post